PDF(Pubmed)
Abstract：
UNASSIGNED: Few studies have explored choroidal changes after cessation of myopia control. This study evaluated the choroidal thickness (ChT) and choroidal vascularity index (CVI) during and after discontinuing long-term low-concentration atropine eye drops use for myopia control.
UNASSIGNED: Children with progressive myopia (6-16 years; n = 153) were randomized to receive 0.01% atropine eye drops or a placebo (2:1 ratio) instilled daily over 2 years, followed by a 1-year washout (no eye drop use). Optical coherence tomography imaging of the choroid was conducted at the baseline, 2-year (end of treatment phase), and 3-year (end of washout phase) visits. The main outcome measure was the subfoveal ChT. Secondary measures include the CVI.
UNASSIGNED: During the treatment phase, the subfoveal choroids in both treatment and control groups thickened by 12-14 µm (group difference P = 0.56). During the washout phase, the subfoveal choroids in the placebo group continued to thicken by 6.6 µm (95% confidence interval [CI] = 1.7 to 11.6), but those in the atropine group did not change (estimate = -0.04 µm; 95% CI = -3.2 to 3.1). Participants with good axial eye growth control had greater choroidal thickening than the fast-progressors during the treatment phase regardless of the treatment group (P < 0.001), but choroidal thickening in the atropine group\'s fast-progressors was not sustained after stopping eye drops. CVI decreased in both groups during the treatment phase, but increased in the placebo group after treatment cessation.
UNASSIGNED: On average, compared to placebo, 0.01% atropine eye drop treatment did not cause a differential rate of change in ChT during treatment, but abrupt cessation of long-term 0.01% atropine eye drops may disrupt normal choroidal thickening in children.
UNASSIGNED: Children with progressive myopia (6-16 years; n = 153) were randomized to receive 0.01% atropine eye drops or a placebo (2:1 ratio) instilled daily over 2 years, followed by a 1-year washout (no eye drop use). Optical coherence tomography imaging of the choroid was conducted at the baseline, 2-year (end of treatment phase), and 3-year (end of washout phase) visits. The main outcome measure was the subfoveal ChT. Secondary measures include the CVI.
UNASSIGNED: During the treatment phase, the subfoveal choroids in both treatment and control groups thickened by 12-14 µm (group difference P = 0.56). During the washout phase, the subfoveal choroids in the placebo group continued to thicken by 6.6 µm (95% confidence interval [CI] = 1.7 to 11.6), but those in the atropine group did not change (estimate = -0.04 µm; 95% CI = -3.2 to 3.1). Participants with good axial eye growth control had greater choroidal thickening than the fast-progressors during the treatment phase regardless of the treatment group (P < 0.001), but choroidal thickening in the atropine group\'s fast-progressors was not sustained after stopping eye drops. CVI decreased in both groups during the treatment phase, but increased in the placebo group after treatment cessation.
UNASSIGNED: On average, compared to placebo, 0.01% atropine eye drop treatment did not cause a differential rate of change in ChT during treatment, but abrupt cessation of long-term 0.01% atropine eye drops may disrupt normal choroidal thickening in children.
摘要：
■很少有研究探讨停止近视控制后的脉络膜变化。这项研究评估了在停止长期使用低浓度阿托品滴眼液控制近视期间和之后的脉络膜厚度（ChT）和脉络膜血管指数（CVI）。
■进行性近视儿童（6-16岁；n=153）被随机分配接受0.01％阿托品滴眼液或安慰剂（2：1比例），每天滴注2年，然后是1年冲洗（不使用滴眼液）。在基线时对脉络膜进行光学相干断层扫描成像，2年（治疗阶段结束），和3年（冲洗阶段结束）访问。主要结果指标是中心凹下ChT。次要措施包括CVI。
■在治疗阶段，治疗组和对照组的中央凹下脉络膜增厚12-14µm(组间差异P=0.56).在冲洗阶段，安慰剂组的中央凹下脉络膜继续增厚6.6µm（95％置信区间[CI]=1.7至11.6），但阿托品组没有变化(估计值=-0.04µm;95%CI=-3.2~3.1).无论治疗组如何，眼轴生长控制良好的参与者在治疗阶段脉络膜增厚大于快速进展者（P<0.001），但阿托品组快速进展者的脉络膜增厚在停止滴眼液后没有持续。治疗期间两组CVI均下降,但安慰剂组在治疗停止后增加。
■平均而言，与安慰剂相比，0.01%阿托品滴眼液治疗期间未引起ChT差异变化率,但长期停用0.01%阿托品滴眼液可能会破坏儿童正常的脉络膜增厚.
■进行性近视儿童（6-16岁；n=153）被随机分配接受0.01％阿托品滴眼液或安慰剂（2：1比例），每天滴注2年，然后是1年冲洗（不使用滴眼液）。在基线时对脉络膜进行光学相干断层扫描成像，2年（治疗阶段结束），和3年（冲洗阶段结束）访问。主要结果指标是中心凹下ChT。次要措施包括CVI。
■在治疗阶段，治疗组和对照组的中央凹下脉络膜增厚12-14µm(组间差异P=0.56).在冲洗阶段，安慰剂组的中央凹下脉络膜继续增厚6.6µm（95％置信区间[CI]=1.7至11.6），但阿托品组没有变化(估计值=-0.04µm;95%CI=-3.2~3.1).无论治疗组如何，眼轴生长控制良好的参与者在治疗阶段脉络膜增厚大于快速进展者（P<0.001），但阿托品组快速进展者的脉络膜增厚在停止滴眼液后没有持续。治疗期间两组CVI均下降,但安慰剂组在治疗停止后增加。
■平均而言，与安慰剂相比，0.01%阿托品滴眼液治疗期间未引起ChT差异变化率,但长期停用0.01%阿托品滴眼液可能会破坏儿童正常的脉络膜增厚.
